LETROZOLE DEXCEL
 |
|
|
Package:
FILM COATED TABLETS: 30 x 2.5 mg.
Dosage:
The recommended dose is 2.5 mg 1 x daily. In the adjuvant and extended adjuvant setting, treatment should continue for 5 years or until tumor relapse occurs, whichever comes first. In patients with metastatic disease, treatment should continue until tumor progression is evident. No dose adjustment is required for elderly patients. No dosage adjustment is required for patients with hepatic impairment or renal impairment (creatinine clearance > 10 ml/min). However, patients with severe hepatic impairment (Child- Pugh score C) should be kept under close supervision. Not for use in children. See prescribing information for full details.
Prescribing Restrictions: None
Indications:
First-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer.
Treatment of advanced breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Contra-Indications:
Known hypersensitivity. Premenopausal women. Pregnancy and lactation. Severe liver disease. See prescribing information for full details.
Special Precautions:
Renal and hepatic impairment. See prescribing information for full details.
Side Effects:
Very common: Arthralgia, hot flushes. Common: Anorexia, appetite increase, hypercholesterolemia. Depression, headache, dizziness. Nausea, vomiting, dyspepsia, constipation, diarrhea, alopecia, increased sweating, rash. Myalgia, bone pain, osteoporosis, bone fractures. Fatigue, peripheral edema, weight increase. See prescribing information for full details.
Drug Interactions:
See prescribing information for full details.
